S&P 500   5,051.41 (-0.21%)
DOW   37,798.97 (+0.17%)
QQQ   431.10 (+0.01%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)
S&P 500   5,051.41 (-0.21%)
DOW   37,798.97 (+0.17%)
QQQ   431.10 (+0.01%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)
S&P 500   5,051.41 (-0.21%)
DOW   37,798.97 (+0.17%)
QQQ   431.10 (+0.01%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)
S&P 500   5,051.41 (-0.21%)
DOW   37,798.97 (+0.17%)
QQQ   431.10 (+0.01%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)

Bionomics (BNOX) Competitors

$0.96
-0.02 (-1.68%)
(As of 03:59 PM ET)

BNOX vs. EFTR, CLVR, KTTA, PCSA, CMMB, CYCN, VCNX, GRTX, CANF, and ATHE

Should you be buying Bionomics stock or one of its competitors? The main competitors of Bionomics include eFFECTOR Therapeutics (EFTR), Clever Leaves (CLVR), Pasithea Therapeutics (KTTA), Processa Pharmaceuticals (PCSA), Chemomab Therapeutics (CMMB), Cyclerion Therapeutics (CYCN), Vaccinex (VCNX), Galera Therapeutics (GRTX), Can-Fite BioPharma (CANF), and Alterity Therapeutics (ATHE). These companies are all part of the "pharmaceutical preparations" industry.

Bionomics vs.

eFFECTOR Therapeutics (NASDAQ:EFTR) and Bionomics (NASDAQ:BNOX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, community ranking, analyst recommendations, media sentiment, profitability, risk and earnings.

In the previous week, eFFECTOR Therapeutics and eFFECTOR Therapeutics both had 2 articles in the media. eFFECTOR Therapeutics' average media sentiment score of 0.44 beat Bionomics' score of 0.29 indicating that Bionomics is being referred to more favorably in the news media.

Company Overall Sentiment
eFFECTOR Therapeutics Neutral
Bionomics Neutral

eFFECTOR Therapeutics presently has a consensus price target of $24.00, indicating a potential upside of 1,106.03%. Bionomics has a consensus price target of $9.00, indicating a potential upside of 837.40%. Given Bionomics' higher possible upside, equities analysts clearly believe eFFECTOR Therapeutics is more favorable than Bionomics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
eFFECTOR Therapeutics
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
Bionomics
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

eFFECTOR Therapeutics received 7 more outperform votes than Bionomics when rated by MarketBeat users. Likewise, 79.31% of users gave eFFECTOR Therapeutics an outperform vote while only 72.73% of users gave Bionomics an outperform vote.

CompanyUnderperformOutperform
eFFECTOR TherapeuticsOutperform Votes
23
79.31%
Underperform Votes
6
20.69%
BionomicsOutperform Votes
16
72.73%
Underperform Votes
6
27.27%

Bionomics has lower revenue, but higher earnings than eFFECTOR Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
eFFECTOR Therapeutics$3.55M2.07-$35.81M-$16.92-0.12
Bionomics$10K785.48-$21.44MN/AN/A

Company Net Margins Return on Equity Return on Assets
eFFECTOR TherapeuticsN/A N/A -160.00%
Bionomics N/A N/A N/A

eFFECTOR Therapeutics has a beta of 0.52, suggesting that its share price is 48% less volatile than the S&P 500. Comparatively, Bionomics has a beta of -0.09, suggesting that its share price is 109% less volatile than the S&P 500.

57.7% of eFFECTOR Therapeutics shares are held by institutional investors. Comparatively, 15.9% of Bionomics shares are held by institutional investors. 8.4% of eFFECTOR Therapeutics shares are held by insiders. Comparatively, 1.5% of Bionomics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

eFFECTOR Therapeutics beats Bionomics on 7 of the 11 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BNOX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BNOX vs. The Competition

MetricBionomicsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$7.86M$6.48B$4.72B$7.48B
Dividend YieldN/A3.10%5.47%3.96%
P/E RatioN/A10.16212.8615.95
Price / Sales785.48316.062,533.3787.51
Price / CashN/A20.4433.4228.19
Price / Book0.355.494.664.27
Net Income-$21.44M$141.46M$100.33M$210.80M
7 Day Performance-7.44%-6.31%-4.91%-5.09%
1 Month Performance-6.54%-5.52%-3.60%-2.61%
1 Year Performance-57.97%1.04%12.24%6.38%

Bionomics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
EFTR
eFFECTOR Therapeutics
1.8029 of 5 stars
$2.31
+8.5%
$24.00
+939.0%
-79.9%$8.52M$3.55M-0.1415Short Interest ↑
High Trading Volume
CLVR
Clever Leaves
0.2529 of 5 stars
$4.81
-1.0%
N/A-52.7%$8.42M$17.42M-0.43400Positive News
Gap Up
KTTA
Pasithea Therapeutics
0 of 5 stars
$8.25
-2.4%
N/A-8.4%$8.59M$20,000.000.0015Gap Down
PCSA
Processa Pharmaceuticals
3.1932 of 5 stars
$2.91
-2.3%
N/A-84.9%$8.32MN/A-0.3915
CMMB
Chemomab Therapeutics
2.0768 of 5 stars
$0.79
flat
$7.00
+786.1%
-54.9%$8.73MN/A-0.3720Short Interest ↑
CYCN
Cyclerion Therapeutics
0 of 5 stars
$3.01
-5.9%
N/A-40.7%$8.16M$1.62M-0.551Short Interest ↓
Gap Down
High Trading Volume
VCNX
Vaccinex
0 of 5 stars
$7.18
+2.1%
N/A-94.5%$8.83M$570,000.00-0.0738Gap Up
GRTX
Galera Therapeutics
0 of 5 stars
$0.16
flat
N/A-94.5%$8.84MN/A-0.1231News Coverage
Positive News
CANF
Can-Fite BioPharma
0.4608 of 5 stars
$2.29
-4.6%
$15.00
+555.0%
N/A$8.11M$740,000.00-1.288Analyst Report
News Coverage
Negative News
Gap Down
ATHE
Alterity Therapeutics
3.4566 of 5 stars
$1.91
+1.6%
$7.00
+266.5%
-14.9%$8.92M$3.37M0.0011Short Interest ↓

Related Companies and Tools

This page (NASDAQ:BNOX) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners